Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes
暂无分享,去创建一个
G. Hospers | J. Haanen | G. Vreugdenhil | J. D. de Groot | A. T. Ten Tije | R. Koornstra | M. Louwman | A. van den Eertwegh | E. Kapiteijn | A. V. van Akkooi | W. Blokx | W. Kruit | F. van den Berkmortel | M. Franken | B. Leeneman | K. Suijkerbuijk | M. Aarts | R. V. van Rijn | M. Schouwenburg | M. Wouters | D. Piersma | M. V. van Zeijl | A. Jochems | J. V. D. van der Hoeven
[1] A. Hauschild,et al. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. , 2017, European journal of cancer.
[2] G. Hospers,et al. Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. , 2017, European journal of cancer.
[3] D. Schadendorf,et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. , 2016, The Lancet. Oncology.
[4] C. Berking,et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.
[5] A. Abernethy,et al. Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study , 2016, Cancer medicine.
[6] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[7] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[8] J. Utikal,et al. A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] C. U. Uyl‐de Groot,et al. A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry , 2015, PharmacoEconomics.
[10] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[11] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[12] A. Hauschild,et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. , 2014, The Lancet. Oncology.
[13] Z. Szallasi,et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma , 2014, Cancer Immunology, Immunotherapy.
[14] Dirk Schadendorf,et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.
[15] R. Dummer,et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. , 2014, European journal of cancer.
[16] F. Hodi,et al. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. , 2013, The oncologist.
[17] P. Ascierto,et al. Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study). , 2012, European journal of cancer.
[18] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[19] Patrick Royston,et al. Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.
[20] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[21] David J Spiegelhalter,et al. Funnel plots for comparing institutional performance , 2005, Statistics in medicine.
[22] M. Gore,et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.